Sana Biotechnology Publishes Gene Editing Research Findings
Sana Biotechnology announced that Nature Biotechnology has published a journal article titled "In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles." The article evaluated a systemically delivered virus-like particle, VLP, using Sana's fusogen technology to target and gene edit hematopoietic stem cells, HSCs, in vivo. Results show potent and cell-specific in vivo gene editing of HSCs in the bone marrow in several murine models, with stable gene-editing of long-term HSCs. Key Findings from The Publication: Optimized VLP enables potent in vivo editing in long-term human HSCs and editing of two hemoglobinopathy-relevant loci, including fetal hemoglobin. Gene-editing VLP with targeted fusogen technology avoids off-target delivery to hepatocytes with systemic delivery.
Trade with 70% Backtested Accuracy
Analyst Views on SANA
About SANA
About the author

Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.

Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.






